"Designing Growth Strategies is in our DNA"

Transthyretin Amyloidosis Treatment Market Size, Share & Industry Analysis, By Drug (Inostersen, Partisiran, Tafamidis, Others), By Indication (Wild Type ATTR amyloidosis, Hereditary ATTR amyloidosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy) and Regional Forecast, 2024-2032

Region :Global | Report ID: FBI101886 | Status : Ongoing

 

KEY MARKET INSIGHTS

In May 2019, the U.S. FDA approved VYNDAQEL (tafamidis meglumine) for the treatment and management of amyloid transthyretin (ATTR) cardiomyopathy, manufactured by Pfizer. Transthyretin amyloidosis is a life-threatening and rare, often fatal disease. There are very few treatment options available for the treatment of transthyretin amyloidosis, as it affects 1.1 people in 100,000 population. There are predominantly two types of transthyretin amyloidosis, namely hereditary transthyretin amyloidosis and wild type Transthyretin amyloidosis. ATTR amyloidosis can affect many organs with symptoms including lumbar spinal stenosis, carpal tunnel syndrome, swelling of feet and legs, loss of appetite, diarrhea, and constipation. The symptoms depend on the affected organ due to the disease. ATTR usually deposits in the heart, spinal canal, writs, and legs. Currently, there is a rising demand for the treatment of ATTR amyloidosis due to the increasing prevalence and increasing need for treatment of the fatal disease.


In the present market scenario, there are very few therapeutic options available for the treatment of ATTR amyloidosis. This is estimated to increase the demand for the drugs currently available in the market. Additionally, the increasing awareness regarding this rare fatal disease in developed countries is estimated to bolster the transthyretin amyloidosis treatment market market growth. Combined with this, improvement in diagnostic procedures, evolving healthcare infrastructure and rapid economic growth of countries is projected to drive the ATTR amyloidosis market growth during the forecast duration.  According to the National Organisation for Rare Disorder (NORD), approximately one in 100,000 Caucasian Americans are affected by ATTR amyloidosis, but the disease is more prevalent in the African American population in the U.S.

Key Market Driver -

Growing need for different treatment options

Key Market Restraint -

Risk of anaphylaxis and blood-borne disease transmission in addition to high cost of transthyretin amyloidosis treatment


However, a liver transplant is considered as the gold standard for the management of ATTR amyloidosis disease. Lack of therapeutic molecules under clinical trials for the treatment of ATTR amyloidosis is estimated to restrain the growth of ATTR amyloidosis market revenue. High cost of treatment, lack of awareness regarding ATTR amyloidosis in developing countries, lack of effective drugs and miss diagnosis of the disease are some of the major restraining factors for the ATTR amyloidosis market.

Key Players Covered:


The major companies covered in the global transthyretin amyloidosis treatment market report include Pfizer Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, and other prominent players.

As per the current transthyretin amyloidosis treatment market trends, retail pharmacy is anticipated to hold the major share of the global transthyretin amyloidosis treatment market due to the high availability of therapeutic drugs through retail channels.

Key Insights:



  • Overview of Regulatory Scenario For Key Countries

  • Pipeline Analysis

  • Key Industry Developments - Mergers, Acquisitions, and Partnerships, 2018

  • Introduction of New Products / Approvals (by Major Players)

  • Epidemiology of Transthyretin Amyloidosis - For Key Countries, 2018


Regional Analysis:


The global transthyretin amyloidosis treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to hold a dominating position in the transthyretin amyloidosis treatment market share owing to higher awareness regarding the rare disease, highly developed healthcare infrastructure, and increasing availability of the treatment. Additionally, the preference of key players to launch therapeutic options for transthyretin amyloidosis treatment in North America is a major transthyretin amyloidosis treatment market drivers for the region.

To gain extensive insights into the market, Request for Customization


On the other hand, in countries such as Germany a France and UK of Europe are expected to follow the lead owing to active government initiatives regarding healthcare infrastructure and availably of trained healthcare professionals. Asia Pacific is projected to register a steady CAGR. The countries of the Asia Pacific, such as Japan, China, and India, are anticipated to witness the higher CAGR in the region during the forecast period. Countries of Latin America and the Middle East and Africa captured a lower transthyretin amyloidosis treatment market share owing to lower awareness regarding the disease and associated therapeutic options.

Segmentation


























 ATTRIBUTE

 DETAILS

By Drug



  • Inostersen

  • Partisiran

  • Tafamidis

  • Others



By Indication



  • Wild Type ATTR amyloidosis

  • Hereditary ATTR amyloidosis



By Distribution Channel



  • Retail Pharmacy

  • Hospital Pharmacy

  • Online Pharmacy



By Geography



  • North America (USA and Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

  • Rest of World



Transthyretin Amyloidosis Treatment Industry Developments



  • In May 2019 Pfizer received U.S FDA approval for Vyndamax (tafamidis) indicated for the treatment of ATTR-CM. It is the first drug approved for the treatment of transthyretin mediated amyloidosis in adults.

  • In October 2018, Ionis Pharmaceuticals, Inc. received U.S FDA approval for the drug Inostersen indicated for the treatment of hereditary ATTR amyloidosis.

  • In August 2018, The U.S FDA approved Partisiran indicated to treat hereditary ATTR amyloidosis which is manufactured by Alnylam Pharmaceuticals.





  • Ongoing
  • 2023
  • 2019-2022

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Ipsos
Ansell
abbvie
Grifols
Lek

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X